Mast Therapeutics Receives a Hold from Maxim Group

By Carrie Williams

Maxim Group analyst Jason McCarthy assigned a Hold rating to Mast Therapeutics (NYSE: MSTX) yesterday. The company’s shares closed yesterday at $0.13.

According to, McCarthy is ranked 0 out of 5 stars with an average return of -12.2% and a 34.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Mateon Therapeutics Inc, and Stellar Biotechnologies.

Mast Therapeutics has an analyst consensus of Hold.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.